Semarion Secures $3.8 Million To Scale Next-generation Cell Assay Technology And Accelerate Pharma Adoption

Semarion, a University of Cambridge spin-out institution from nan Cavendish Laboratory combining materials engineering and compartment biology to tackle unmet supplier screening needs, coming announced it has raised $3.8 cardinal USD (£2.9 cardinal GBP). The fundraise was led by Parkwalk, and joined by The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The finance will facilitate commercialized description and standard manufacturing of nan Company's SemaCyte® level which enables adherent compartment models to beryllium handled arsenic assay-ready, barcoded reagents for much flexible, data-rich, scalable supplier discovery.

Image Credit: Semarion

With a increasing pipeline of opportunities and beardown manufacture interest, Semarion is focused connected broad-scale customer adoption, strengthening partnerships and preparing for its adjacent shape of growth. The backing will beryllium utilized to thrust further commercialization of nan SemaCyte platform, enabling nan Company to summation manufacturing throughput and grow nan section exertion support team.

Semarion's exertion has already been adopted by starring world pharmaceutical organizations, including apical 10 pharma companies, crossed nan US and Europe, pinch aggregate aviator programs progressing towards broader commercialized rollout. The Company has besides established collaborations pinch world life subject devices providers including Revvity, which has integrated compatibility for SemaCyte discovery into its imaging and study platforms, and SPT Labtech, combining nan microcarrier exertion pinch SPT Labtech's liquid handling level to beforehand automated cell-based assay workflows.

This caller backing is successful summation to nan Company's $2.89 cardinal USD Seed round, which was raised successful 2022.

Parkwalk is excited to beryllium supporting nan improvement of Semarion's exertion that has nan imaginable to make a measurement alteration successful cell-based research, accelerating a captious way successful supplier discovery. We are backing a squad that has proven it tin execute successful delivering a merchandise that useful and tin beryllium adopted successful customer workflows. This backing will let Semarion to scale, reaching its afloat imaginable and creating worth for investors and making a real-world impact."

John Pearson, Chief Investment Officer, Parkwalk

Karin Boettcher, Product Manager High-Content Screening, Revvity, commented: "Semarion's attack aligns powerfully pinch nan industry's increasing request for much scalable, information-rich cell-based workflows. Their unsocial usage of optically barcoded compartment microcarriers opens up breathtaking caller possibilities for high-content screening and profiling, helping researchers make richer datasets without sacrificing throughput. We person greatly enjoyed moving pinch nan Semarion squad and look guardant to continuing our collaboration to beforehand next-generation supplier find workflows."

Jeroen Verheyen, CEO and Co-Founder astatine Semarion, added: "This backing marks an important measurement arsenic we standard to meet increasing request from nan industry. Scientists are nether expanding unit to make much cell-based data, amended automation and thrust operational efficiency. SemaCytes alteration them to do this wrong existing workflows and infrastructure, and we are now focused connected translating that momentum into broader adoption."